Lifeboat Foundation

The elevated cardiovascular disease risk among people with HIV is even greater than predicted by a standard risk calculator in several groups, including Black people and cisgender women, according to analyses from a large international clinical trial primarily funded by the National institutes of Health and presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver. The risk of having a first major cardiovascular event was also higher than previously predicted for people from high-income regions and those whose HIV replication was not suppressed below detectable levels.

Researchers examined the incidence of major adverse cardiovascular events in people who did not take pitavastatin or other statins during the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) trial, a large clinical trial to test whether pitavastatin—a cholesterol-lowering drug known to prevent cardiovascular disease—could prevent major adverse cardiovascular events, such as heart attacks and strokes, in people with HIV. The scientists compared the incidence of cardiovascular events in the trial to the incidence predicted by standard estimates, which use the American College of Cardiology and American Heart Association’s Pooled Cohort Risk Equations (PCE) score.

They found that the rate of cardiovascular events occurring in many groups of people differed from predicted rates, even considering that people with HIV have a higher overall risk of cardiovascular disease than people without HIV, including double the risk of major adverse cardiovascular events. Notably, in high-income regions—as defined by the global burden of disease classification system—including North and South America and Europe, cardiovascular event rates were higher overall, with cisgender women experiencing about two and a half times more events than predicted, and Black participants having more than 50% higher event rates than predicted.

Organoids of multiple different tissue types can be generated from cells collected from amniotic fluid samples, without termination of the pregnancy, according to a study in Nature Medicine.

The generation of primary organoids, from fetal fluid-derived epithelial stem or progenitor cells, offers the possibility of modeling different developing tissues during gestation, even beyond the limits of pregnancy termination.

New method will help scientists study neural networks and neuroplastic changes underlying higher brain functions and disease processes in model animals.

NIH-supported study shows long-term benefits of surgery compared to medication and lifestyle change.

People with type 2 diabetes who underwent bariatric surgery achieved better long-term blood glucose control compared to people who received medical management plus lifestyle interventions, according to a new study supported by the National Institutes of Health. The participants who underwent bariatric surgery, also called metabolic or weight-loss surgery, were also more likely to stop needing diabetes medications and had higher rates of diabetes remission up to 12 years post-surgery. Results of the study were published in JAMA and funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of NIH.

“While there are many factors involved, and not all of them are completely understood, bariatric surgery typically results in greater weight loss that affects a person’s metabolic hormones, which improves the body’s response to insulin and ability to maintain healthy blood glucose levels,” said Dr. Jean Lawrence, NIDDK project scientist. “These results show that people with overweight or obesity and type 2 diabetes can make long-term improvements in their health and change the trajectory of their diabetes through surgery.”

https://www.youtube.com/watch?app=desktop&v=qn8ahPBFVSs

Here Dr Tan introduces geranylgeraniol (GG), talks about its discovery and its importance in human metabolism.

Wellness Extract 5% discount Code MODERN10
GG Essential https://collabs.shop/ivoshz.
Vitamin E, Delta Gold https://collabs.shop/gfjyof.
Bio Quinol with GG https://collabs.shop/wm9cce.
Renue By Science 10% : Code MHS https://tinyurl.com/35jyuk33
CoQ10 https://bit.ly/4bX3I6P\r.
ProHealth 15% discount Code MODERN: https://prohealth.pxf.io/Vm9BoA
CoQ10 https://prohealth.pxf.io/LX12N0
DoNotAge 10% discount code MHS https://tinyurl.com/6dbvhv87
Pure NMN https://tinyurl.com/wyzj2f3d.
Nuchido Time+ 20% discount of first purchase with code MODERN20 https://nuchido.com/MODERN
NOVOS https://novos.sjv.io/QyWP7o code 5OFFMHS
NMN Bio 10% off all products https://tinyurl.com/2af2v2fw Code ModernHealthSpan10 in link.
☕If you would like to support our channel, we’d love a coffee…thank you! https://www.buymeacoffee.com/mhealthspan.

Continue reading “A Promising Novel Anti-Aging Compound GG — Geranylgeraniol Explained By It Discoverer Dr Barrie Tan” »

In a collaborative study, researchers from Kyushu University and Harvard Medical School have identified proteins that can turn or “reprogram” fibroblasts—the most commonly found cells in skin and connective tissue—into cells with similar properties to limb progenitor cells. Publishing in Developmental Cell, the researchers’ findings have enhanced our understanding of limb development and have set the stage for regenerative therapy in the future.

Globally, close to 60 million people are living with limb loss. Amputations can result from various medical conditions such as tumors, infections, and birth defects, or due to trauma from industrial accidents, traffic accidents, and natural disasters such as earthquakes. People with limb injuries often rely on synthetic materials and metal prostheses, but many researchers are studying the process of limb development, with the aim of bringing regenerative therapy, or natural tissue replacement, one step closer as a potential treatment.

“During limb development in the embryo, limb progenitor cells in the limb bud give rise to most of the different limb tissues, such as bone, muscle, cartilage and tendon. It’s therefore important to establish an easy and accessible way of making these cells,” explains Dr. Yuji Atsuta, lead researcher who began tackling this project at Harvard Medical School and continues it as a lecturer at Kyushu University’s Graduate School of Sciences.

Researchers find evidence that intestinal bacteria could be altering immune cells in lungs enabling them to fight respiratory virus infection.

K-Ras mutations are all too familiar as drivers of cancer. And until recently, they were considered all but undruggable. But ever since the arrival of sotorasib and adagrasib—two FDA-approved K-Ras-G12C inhibitors—K-Ras mutations have had the distinction of being somewhat druggable. Even better, K-Ras mutations may soon become yet more druggable. Scientists at the University of California, San Francisco, have found a way to target K-Ras-G12D mutations, which are especially prevalent in pancreatic ductal adenocarcinoma.

The scientists were led by Kevan Shokat, PhD, a professor in the department of cellular and molecular pharmacology. Back in 2013, Shokat and colleagues developed the first K-Ras-G12C inhibitors. And today, in Nature Chemical Biology, they present a paper (“Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D”) describing how they designed a candidate drug that could help make pancreatic cancer, which is almost always fatal, a treatable and perhaps even curable condition.

“[Covalent] inhibition of G12D, the most frequent K-Ras mutation particularly prevalent in pancreatic ductal adenocarcinoma, has remained elusive due to the lack of aspartate-targeting chemistry,” the article’s authors wrote. “Here we present a set of malolactone-based electrophiles that exploit ring strain to crosslink K-Ras-G12D at the mutant aspartate to form stable covalent complexes.”

An endoscopic mapping device, developed over the course of a decade by scientists at the Auckland Bioengineering Institute, consists of an inflatable sphere covered in sensors, delivered down the esophagus and able to measure electrical activity in the gut.

In the same way, abnormal heart electrical signals can cause serious heart problems, research has found faulty bioelectric gut waves can lead to stomach pain, nausea, vomiting and bloating.

But often doctors can’t find out what the problem is. That’s because gut electrics aren’t nearly as strong or as easily measured as heart waves; without surgery it’s hard to know if someone has a so-called ‘dysrhythmic’ gut—and if so, where the problem is.